<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-11-21T06:11:50Z</responseDate><request verb="GetRecord" identifier="oai:macsphere.mcmaster.ca:11375/6751" metadataPrefix="dim">https://prod-ms-be.lib.mcmaster.ca/server/oai/request</request><GetRecord><record><header><identifier>oai:macsphere.mcmaster.ca:11375/6751</identifier><datestamp>2026-09-24T19:44:51Z</datestamp><setSpec>com_11375_271</setSpec><setSpec>col_11375_272</setSpec></header><metadata><dim:dim xmlns:dim="http://www.dspace.org/xmlns/dspace/dim" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://www.dspace.org/xmlns/dspace/dim http://www.dspace.org/schema/dim.xsd">
   <dim:field mdschema="dc" element="contributor" qualifier="advisor" lang="en_US">Atkinson, S.A.</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="author" lang="en_US">Ward, Elizabeth Wendy</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="department" lang="en_US">Medical Sciences</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="accessioned">2014-06-18T16:36:46Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="available">2014-06-18T16:36:46Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="created" lang="en_US">2010-06-02</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="issued" lang="en_US">1998-07</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="other" lang="en_US">opendissertations/2060</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="other" lang="en_US">2840</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="other" lang="en_US">1339737</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="uri">http://hdl.handle.net/11375/6751</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="uri">https://doi.org/10.71548/8495</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="abstract" lang="en_US">&lt;p>Dexamethasone (DEX) treatment in very preterm infants has proven to facilitate earlier weaning from mechanical ventilation and supplemental oxygen, thereby lessening the severity of lung disease incurred by long-term oxygen dependency. However, DEX therapy is not without negative side-effects; studies in preterm infants and piglets have reported DEX-induced impairments in growth and bone mineral metabolism. DEX may act by altering the concentration or activity of specific components of the growth hormone (GH)/insulin-like growth factor (IGF-I) axis which are essential for regulating growth and bone mass. The first study, in preterm infants, characterized how DEX alters the circulating components of the GH-IGF-I axis and suggested potential mechanisms by which DEX delays growth and bone development as both plasma IGF-I and biochemical markers of bone metabolism were reduced during DEX. The objectives of the piglet studies were to delineate the effectiveness of adjunctive GH or GH+IGF-I to counter the detrimental effects of DEX on growth, protein turnover and bone mass. In the first studies, we administered GH, GH+IGF-I or placebo to piglets while they received a two week course of DEX. GH and GH+IGF-I partially attenuated the reductions in growth and bone mas to a similar extent. Only with respect to protein metabolism was an additional benefit observed with combined treatment (GH+IGF-I). A dose-response study revealed the minimal effective GH dose, and demonstrated that bone cell activity and weight and length gain returned to control levels during a period of rehabilitation in which no DEX or GH were administered. Currently, it is uncertain if DEX-treated infants experience similar metabolic improvements in weight and length growth or bone mineral mass post-DEX treatment or whether the metabolic insults of DEX are sustained. Longer term follow-up of DEX-treated preterm infants is required to fully comprehend to long-term consequences of DEX on growth into childhood. If there are long-term effects on growth and bone development, future studies should focus on whether GH is more effective post-DEX compared to during DEX treatment or whether adjunctive administration of other anabolic agents will counter the negative effects of DEX during development.&lt;/p></dim:field>
   <dim:field mdschema="dc" element="description" qualifier="degree" lang="en_US">Doctor of Philosophy (PhD)</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">Medical Sciences</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">Medical Sciences</dim:field>
   <dim:field mdschema="dc" element="title" lang="en_US">Steroid-induced growth delay and bone abnormalities in preterm infants and piglets during early development: the interaction of steroids and the GH-IGF-I axis</dim:field>
   <dim:field mdschema="dc" element="type" lang="en_US">thesis</dim:field>
   <dim:field mdschema="others" element="access-status">open.access</dim:field>
</dim:dim></metadata></record></GetRecord></OAI-PMH>